Interesting facts
Interesting Facts about 1-(Cyclohexoxycarbonyloxy)ethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
This compound, often referred to in scientific discussions as a specialized organic molecule, showcases an intricate structure that is a fusion of various chemical functionalities. Here are some compelling points regarding this compound:
- Diverse Functional Groups: This molecule features an array of functional groups, including ethoxy, carbonyloxy, and tetrazole, which all contribute to its unique chemical behavior and potential applications in medicinal chemistry.
- Pharmacological Potential: The presence of the tetrazole ring has been linked to various biological activities, making this compound a subject of interest in drug discovery processes. Tetrazoles are often used in the development of pharmaceuticals due to their ability to enhance bioavailability.
- Synergistic Interactions: The combination of the benzimidazole core with other aromatic systems may result in synergistic effects that could modify the compound's efficacy in biological contexts, potentially impacting its pharmacodynamics and pharmacokinetics.
Researchers are continually interested in exploring the intricate interactions of such compounds, especially in fields such as:
- Medicinal Chemistry
- Drug Design and Development
- Agricultural Chemistry
As stated by renowned chemist Robert H. Grubbs, “The best way to prepare for the future is to invent it.” This sentiment resonates with the exploration of complex molecules like this one, which hold promise for fostering innovation in therapy and treatment methodologies.
Continued investigation into the biological activities and synthesis routes of compounds like 1-(cyclohexoxycarbonyloxy)ethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate may unlock potential breakthroughs in the pharmaceutical sector.
Synonyms
Candesartan cilexetil
145040-37-5
Atacand
TCV-116
Amias
Parapres
candesartancilexetil
Kenzen
CANDESARTAN CILEXTIL
TCV 116
Candesartan cilexetil [USAN]
Ratacand
MFCD00871371
NSC-758697
UNII-R85M2X0D68
DTXSID5020239
R85M2X0D68
CHEMBL1014
DTXCID50239
CHEBI:3348
1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
TCY 116
NSC 758697
1-(cyclohexyloxycarbonyloxy)ethyl 1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate
Candesartan 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester
CANDESARTAN CILEXETIL (MART.)
CANDESARTAN CILEXETIL [MART.]
CANDESARTAN CILEXETIL (USP-RS)
CANDESARTAN CILEXETIL [USP-RS]
1-(((cyclohexyloxy)carbonyl)oxy)ethyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate
1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID, 2-ETHOXY-1-((2'-(1H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-, 1-(((CYCLOHEXYLOXY)CARBONYL)OXY)ETHYL ESTER, (+/-)-
candesartan cilexitil
CANDESARTAN CILEXETIL (EP MONOGRAPH)
CANDESARTAN CILEXETIL [EP MONOGRAPH]
CANDESARTAN CILEXETIL (USP MONOGRAPH)
CANDESARTAN CILEXETIL [USP MONOGRAPH]
Candesartan 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester
Racanda
Candesartan hexetil
2-Ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid 1-[[(cyclohexyloxy)carbonyl]oxy]et hyl ester;Atacand;Blopress
Atacand (TN)
Candesartan cilexetil?
Spectrum_001707
Candesartan (Cilexetil)
Spectrum2_000485
Spectrum3_000996
Spectrum4_001124
Spectrum5_001462
Candesartan Celexetil Ester
SCHEMBL40831
BSPBio_002691
KBioGR_001607
KBioSS_002187
1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate
1H-Benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)-
MLS004774127
Candesartan cilexetil , 97%
SPECTRUM1504261
SPBio_000349
GTPL8352
Candesartan cilexetil (Atacand)
Candesartan Cilexetil (Standard)
KBio2_002187
KBio2_004755
KBio2_007323
KBio3_001911
HMS1922J09
HMS2093E20
HMS3651I08
Pharmakon1600-01504261
Candesartan cilexetil (JP18/USP)
CANDESARTAN CILEXETIL [JAN]
BCP22050
Tox21_302202
AC-204
BDBM50318907
CANDESARTAN CILEXETIL [VANDF]
CCG-39530
HY-17505R
NSC758697
s2037
STL451065
AKOS015894954
AKOS015920180
CANDESARTAN CILEXETIL [WHO-DD]
AB07617
BCP9000480
CCG-222334
DB00796
DS-1302
FC19661
KS-1147
Candesartan cilexetil, >=98% (HPLC)
NCGC00095123-01
NCGC00095123-02
NCGC00095123-03
NCGC00095123-05
NCGC00095123-10
NCGC00095123-16
NCGC00255218-01
(+-)-1-Hydroxyethyl 2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester)
1-[[(cyclohexyloxy)carbonyl]oxy]ethyl 2-ethoxy-1-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-benzimidazole-7-carboxylate
1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate
1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester, (+-)-
2-ETHOXY-1-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID 1-[[(CYCLOHEXYLOXY)CARBONYL]OXY]ETHYL ESTER
2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester
BC164274
Candesartan cilexetil - Bio-X trade mark
HY-17505
SMR003500784
SY051248
CANDESARTAN CILEXETIL [ORANGE BOOK]
SBI-0206767.P001
C2635
CAS-145040-37-5
NS00006138
SW220041-1
C07709
D00626
EN300-118698
AB01274805-01
AB01274805_02
AB01274805_03
H212/91
L006257
SR-05000001976
SR-05000001976-1
BRD-A65671304-001-02-6
BRD-A65671304-001-03-4
BRD-A65671304-001-07-5
BRD-A65671304-001-08-3
Q27075664
Z1515383338
CANDESARTAN 1-(((CYCLOHEXYLOXY)CARBONYL)OXY)ETHYL ESTER [MI]
Candesartan cilexetil, European Pharmacopoeia (EP) Reference Standard
Candesartan cilexetil, United States Pharmacopeia (USP) Reference Standard
Candesartan cilexetil for peak identification, European Pharmacopoeia (EP) Reference Standard
Candesartan cilexetil for system suitability, European Pharmacopoeia (EP) Reference Standard
Candesartan Cilexetil, Pharmaceutical Secondary Standard; Certified Reference Material
(+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methylbenzimidazole-7-carboxylate
(+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methylbenzimidazole-7-carboxylate
(+/-)-1-HYDROXYETHYL 2-ETHOXY-1-(P-(O-1H-TETRAZOL-5-YLPHENYL)BENZYL)-7-BENZIMIDAZOLECARBOXYLATE, CYCLOHEXYL CARBONATE (ESTER)
(+/-)1-HYDROXYETHYL 2-ETHOXY-1-(P-(O-1H-TETRAZOL-5-YLPHENYL)BENZYL)-7-BENZIMIDAZOLECARBOXYLATE, CYCLOHEXYL CARBONATE (ESTER)
1-(((Cyclohexyloxy)carbonyl)oxy)ethyl1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate
1-(Cyclohexyloxycarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazol-7-carboxylate
1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-1,3-benzodiazole-7-carboxylate
1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl] methyl]benzimidazole-4-carboxylate
2-Ethoxy-3-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester
2-Ethoxy-3-[2''-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester
2-ethoxy-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid 1-cyclohe
Solubility of 1-(Cyclohexoxycarbonyloxy)ethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
The solubility of 1-(cyclohexoxycarbonyloxy)ethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate, with the chemical formula C33H34N6O6, can be quite intricate due to its complex structure. Understanding its solubility characteristics is crucial for various applications, especially in pharmaceuticals.
Key Factors Affecting Solubility:
In practical terms, it might be expected that this compound exhibits moderate solubility in organic solvents such as dichloromethane or methanol due to its hydrophobic characters, while showing limited solubility in water. This solubility profile could significantly influence its bioavailability and pharmacokinetic properties.
In summary, exploring the solubility of this compound is essential for its practical applications, making the understanding of its physicochemical properties vital for chemists and formulators alike.